Trial Profile
Follow up study on LC of PEGASYS/COPEGUS in Phase II/III
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C; Liver cancer; Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 30 May 2012 New trial record